BRISTOL-MYERS SQUIBB COMPANY Selling, General and Administrative Expense
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Selling, General and Administrative Expense of $1.83 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-07-30
- BRISTOL-MYERS SQUIBB COMPANY selling, general and administrative expense for the quarter ending 2026-06-30 was $1.83B, a 6.60% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY selling, general and administrative expense for the quarter ending 2026-03-31 was $1.62B, a 2.08% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY selling, general and administrative expense for the quarter ending 2025-12-31 was $2.18B, a 2.11% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY selling, general and administrative expense for the quarter ending 2025-09-30 was $1.79B, a 9.78% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY selling, general and administrative expense for fiscal 2025 was $7.27B, a 13.63% decline from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY selling, general and administrative expense for fiscal 2024 was $8.41B, a 8.26% increase from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY selling, general and administrative expense for fiscal 2023 was $7.77B, a 0.54% decline from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY selling, general and administrative expense for fiscal 2022 was $7.81B, a 1.61% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.83B 10-Q · filed 2026-07-30 | $3.44B 10-Q · filed 2026-07-30 | $5.62B derived: sum of 3 quarters · filed 2026-07-30 | $7.41B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | $1.62B 10-Q · filed 2026-04-30 | $3.80B derived: sum of 2 quarters · filed 2026-04-30 | $5.59B derived: sum of 3 quarters · filed 2026-04-30 | $7.30B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | $2.18B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $3.97B derived: sum of 2 quarters · filed 2026-02-11 | $5.68B derived: sum of 3 quarters · filed 2026-07-30 | $7.27B 10-K · filed 2026-02-11 | ||||
| 2025-09-30 | $1.79B 10-Q · filed 2025-10-30 | $3.50B derived: sum of 2 quarters · filed 2026-07-30 | $5.09B 10-Q · filed 2025-10-30 | $7.22B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | $1.71B 10-Q · filed 2026-07-30 | $3.30B 10-Q · filed 2026-07-30 | $5.43B derived: sum of 3 quarters · filed 2026-07-30 | $7.42B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | $1.58B 10-Q · filed 2026-04-30 | $3.72B derived: sum of 2 quarters · filed 2026-04-30 | $5.70B derived: sum of 3 quarters · filed 2026-04-30 | $7.63B derived: sum of 4 quarters · filed 2026-04-30 | ||||
| 2024-12-31 | $2.14B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $4.12B derived: sum of 2 quarters · filed 2026-02-11 | $6.05B derived: sum of 3 quarters · filed 2026-02-11 | $8.41B 10-K · filed 2026-02-11 | ||||
| 2024-09-30 | $1.98B 10-Q · filed 2025-10-30 | $3.91B derived: sum of 2 quarters · filed 2025-10-30 | $6.28B 10-Q · filed 2025-10-30 | $8.35B derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-06-30 | $1.93B 10-Q · filed 2025-07-31 | $4.29B 10-Q · filed 2025-07-31 | $6.37B derived: sum of 3 quarters · filed 2026-02-11 | $8.37B derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-03-31 | $2.37B 10-Q · filed 2025-04-24 | $4.44B derived: sum of 2 quarters · filed 2026-02-11 | $6.44B derived: sum of 3 quarters · filed 2026-02-11 | $8.38B derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2023-12-31 | $2.07B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $4.08B derived: sum of 2 quarters · filed 2026-02-11 | $6.01B derived: sum of 3 quarters · filed 2026-02-11 | $7.77B 10-K · filed 2026-02-11 | ||||
| 2023-09-30 | $2.00B 10-Q · filed 2024-10-31 | $3.94B derived: sum of 2 quarters · filed 2024-10-31 | $5.70B 10-Q · filed 2024-10-31 | $7.96B derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2023-06-30 | $1.93B 10-Q · filed 2024-07-26 | $3.70B 10-Q · filed 2024-07-26 | $5.96B derived: sum of 3 quarters · filed 2025-02-12 | $7.89B derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2023-03-31 | $1.76B 10-Q · filed 2024-04-25 | $4.03B derived: sum of 2 quarters · filed 2025-02-12 | $5.96B derived: sum of 3 quarters · filed 2025-02-12 | $7.75B derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2022-12-31 | $2.27B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $4.20B derived: sum of 2 quarters · filed 2025-02-12 | $5.98B derived: sum of 3 quarters · filed 2025-02-12 | $7.81B 10-K · filed 2025-02-12 | ||||
| 2022-09-30 | $1.93B 10-Q · filed 2023-10-26 | $3.72B derived: sum of 2 quarters · filed 2023-10-26 | $5.55B 10-Q · filed 2023-10-26 | $7.90B derived: sum of 4 quarters · filed 2024-02-13 | ||||
| 2022-06-30 | $1.79B 10-Q · filed 2023-07-27 | $3.62B 10-Q · filed 2023-07-27 | $5.97B derived: sum of 3 quarters · filed 2024-02-13 | $7.76B derived: sum of 4 quarters · filed 2024-02-13 | ||||
| 2022-03-31 | $1.83B 10-Q · filed 2023-04-27 | $4.18B derived: sum of 2 quarters · filed 2024-02-13 | $5.97B derived: sum of 3 quarters · filed 2024-02-13 | $7.86B derived: sum of 4 quarters · filed 2024-02-13 | ||||
| 2021-12-31 | $2.35B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $4.14B derived: sum of 2 quarters · filed 2024-02-13 | $6.02B derived: sum of 3 quarters · filed 2024-02-13 | $7.69B 10-K · filed 2024-02-13 | ||||
| 2021-09-30 | $1.79B 10-Q · filed 2022-10-26 | $3.67B derived: sum of 2 quarters · filed 2022-10-26 | $5.34B 10-Q · filed 2022-10-26 | $8.06B derived: sum of 4 quarters · filed 2023-02-14 | ||||
| 2021-06-30 | $1.88B 10-Q · filed 2022-07-27 | $3.55B 10-Q · filed 2022-07-27 | $6.27B derived: sum of 3 quarters · filed 2023-02-14 | $7.97B derived: sum of 4 quarters · filed 2023-02-14 | ||||
| 2021-03-31 | $1.67B 10-Q · filed 2022-04-29 | $4.39B derived: sum of 2 quarters · filed 2023-02-14 | $6.09B derived: sum of 3 quarters · filed 2023-02-14 | $7.72B derived: sum of 4 quarters · filed 2023-02-14 | ||||
| 2020-12-31 | $2.72B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $4.43B derived: sum of 2 quarters · filed 2023-02-14 | $6.05B derived: sum of 3 quarters · filed 2023-02-14 | $7.66B 10-K · filed 2023-02-14 | ||||
| 2020-09-30 | $1.71B 10-Q · filed 2021-10-27 | $3.33B derived: sum of 2 quarters · filed 2021-10-27 | $4.94B 10-Q · filed 2021-10-27 | $6.67B derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-06-30 | $1.63B 10-Q · filed 2021-07-28 | $3.23B 10-Q · filed 2021-07-28 | $4.97B derived: sum of 3 quarters · filed 2022-02-09 | $6.02B derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-03-31 | $1.61B 10-Q · filed 2021-04-29 | $3.34B derived: sum of 2 quarters · filed 2022-02-09 | $4.39B derived: sum of 3 quarters · filed 2022-02-09 | $5.47B derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2019-12-31 | $1.73B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $2.79B derived: sum of 2 quarters · filed 2022-02-09 | $3.87B derived: sum of 3 quarters · filed 2022-02-09 | $4.87B 10-K · filed 2022-02-09 | ||||
| 2019-09-30 | $1.05B 10-Q · filed 2020-11-05 | $2.13B derived: sum of 2 quarters · filed 2020-11-05 | $3.14B 10-Q · filed 2020-11-05 | $4.47B derived: sum of 4 quarters · filed 2021-02-10 | ||||
| 2019-06-30 | $1.08B 10-Q · filed 2020-08-06 | $2.08B 10-Q · filed 2020-08-06 | $3.42B derived: sum of 3 quarters · filed 2021-02-10 | $4.52B derived: sum of 4 quarters · filed 2021-02-10 | ||||
| 2019-03-31 | $1.01B 10-Q · filed 2020-05-07 | $2.34B derived: sum of 2 quarters · filed 2021-02-10 | $3.45B derived: sum of 3 quarters · filed 2021-02-10 | $4.58B derived: sum of 4 quarters · filed 2021-02-10 | ||||
| 2018-12-31 | $1.34B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-10 | $2.44B derived: sum of 2 quarters · filed 2021-02-10 | $3.57B derived: sum of 3 quarters · filed 2021-02-10 | $4.55B 10-K · filed 2021-02-10 | ||||
| 2018-09-30 | $1.10B 10-Q · filed 2019-10-31 | $2.23B derived: sum of 2 quarters · filed 2019-10-31 | $3.21B 10-Q · filed 2019-10-31 | $4.53B derived: sum of 4 quarters · filed 2020-02-24 | ||||
| 2018-06-30 | $1.13B 10-Q · filed 2019-07-25 | $2.11B 10-Q · filed 2019-07-25 | $3.43B derived: sum of 3 quarters · filed 2020-02-24 | $4.59B derived: sum of 4 quarters · filed 2020-02-24 | ||||
| 2018-03-31 | $980.00M 10-Q · filed 2019-04-25 | $2.30B derived: sum of 2 quarters · filed 2020-02-24 | $3.46B derived: sum of 3 quarters · filed 2020-02-24 | $4.65B derived: sum of 4 quarters · filed 2020-02-24 | ||||
| 2017-12-31 | $1.32B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $2.48B derived: sum of 2 quarters · filed 2020-02-24 | $3.67B derived: sum of 3 quarters · filed 2020-02-24 | $4.75B 10-K · filed 2020-02-24 | $4.69B 10-K · filed 2018-02-13 | |||
| 2017-09-30 | $1.16B 10-Q · filed 2018-10-25 | $1.15B 10-Q · filed 2017-10-26 | $2.35B derived: sum of 2 quarters · filed 2018-10-25 | $3.44B 10-Q · filed 2018-10-25 | $3.39B 10-Q · filed 2017-10-26 | $4.96B derived: sum of 4 quarters · filed 2019-02-25 | ||
| 2017-06-30 | $1.19B 10-Q · filed 2018-07-26 | $1.17B 10-Q · filed 2017-07-27 | $2.27B 10-Q · filed 2018-07-26 | $2.24B 10-Q · filed 2017-07-27 | $3.80B derived: sum of 3 quarters · filed 2019-02-25 | $4.95B derived: sum of 4 quarters · filed 2019-02-25 | ||
| 2017-03-31 | $1.08B 10-Q · filed 2018-04-26 | $1.07B 10-Q · filed 2017-04-27 | $2.61B derived: sum of 2 quarters · filed 2019-02-25 | $3.76B derived: sum of 3 quarters · filed 2019-02-25 | $5.00B derived: sum of 4 quarters · filed 2019-02-25 | |||
| 2016-12-31 | $1.53B derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | $2.67B derived: sum of 2 quarters · filed 2019-02-25 | $3.91B derived: sum of 3 quarters · filed 2019-02-25 | $4.98B 10-K · filed 2019-02-25 | $4.91B 10-K · filed 2017-02-21 | |||
| 2016-09-30 | $1.14B 10-Q · filed 2017-10-26 | $2.38B derived: sum of 2 quarters · filed 2017-10-26 | $3.45B 10-Q · filed 2017-10-26 | $4.95B derived: sum of 4 quarters · filed 2018-02-13 | ||||
| 2016-06-30 | $1.24B 10-Q · filed 2017-07-27 | $2.31B 10-Q · filed 2017-07-27 | $3.81B derived: sum of 3 quarters · filed 2018-02-13 | $4.98B derived: sum of 4 quarters · filed 2018-02-13 | ||||
| 2016-03-31 | $1.07B 10-Q · filed 2017-04-27 | $2.57B derived: sum of 2 quarters · filed 2018-02-13 | $3.75B derived: sum of 3 quarters · filed 2018-02-13 | $4.88B derived: sum of 4 quarters · filed 2018-02-13 | ||||
| 2015-12-31 | $1.50B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $2.68B derived: sum of 2 quarters · filed 2018-02-13 | $3.81B derived: sum of 3 quarters · filed 2018-02-13 | $4.84B 10-K · filed 2018-02-13 | ||||
| 2015-09-30 | $1.18B 10-Q · filed 2016-10-27 | $983.00M 10-Q · filed 2015-10-27 | $2.31B derived: sum of 2 quarters · filed 2016-10-27 | $3.34B 10-Q · filed 2016-10-27 | $2.85B 10-Q · filed 2015-10-27 | $5.22B derived: sum of 4 quarters · filed 2017-02-21 | ||
| 2015-06-30 | $1.14B 10-Q · filed 2016-07-28 | $968.00M 10-Q · filed 2015-07-23 | $2.16B 10-Q · filed 2016-07-28 | $1.86B 10-Q · filed 2015-07-23 | $4.05B derived: sum of 3 quarters · filed 2017-02-21 | $5.08B derived: sum of 4 quarters · filed 2017-02-21 | ||
| 2015-03-31 | $1.03B 10-Q · filed 2016-04-28 | $894.00M 10-Q · filed 2015-04-28 | $2.91B derived: sum of 2 quarters · filed 2017-02-21 | $3.94B derived: sum of 3 quarters · filed 2017-02-21 | $4.89B derived: sum of 4 quarters · filed 2017-02-21 | |||
| 2014-12-31 | $1.89B derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $2.91B derived: sum of 2 quarters · filed 2017-02-21 | $3.87B derived: sum of 3 quarters · filed 2017-02-21 | $4.82B 10-K · filed 2017-02-21 | $4.09B 10-K · filed 2015-02-13 | |||
| 2014-09-30 | $1.03B 10-Q · filed 2015-10-27 | $1.98B derived: sum of 2 quarters · filed 2015-10-27 | $2.94B 10-Q · filed 2015-10-27 | $4.86B derived: sum of 4 quarters · filed 2016-02-12 | ||||
| 2014-06-30 | $951.00M 10-Q · filed 2015-07-23 | $1.91B 10-Q · filed 2015-07-23 | $3.83B derived: sum of 3 quarters · filed 2016-02-12 | $4.81B derived: sum of 4 quarters · filed 2016-02-12 | ||||
| 2014-03-31 | $957.00M 10-Q · filed 2015-04-28 | $2.88B derived: sum of 2 quarters · filed 2016-02-12 | $3.86B derived: sum of 3 quarters · filed 2016-02-12 | $4.90B derived: sum of 4 quarters · filed 2016-02-12 | ||||
| 2013-12-31 | $1.92B derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $2.90B derived: sum of 2 quarters · filed 2016-02-12 | $3.94B derived: sum of 3 quarters · filed 2016-02-12 | $4.94B 10-K · filed 2016-02-12 | $4.08B 10-K · filed 2014-02-14 | |||
| 2013-09-30 | $980.00M 10-Q · filed 2014-10-24 | $2.02B derived: sum of 2 quarters · filed 2014-10-24 | $3.02B 10-Q · filed 2014-10-24 | $4.16B derived: sum of 4 quarters · filed 2015-02-13 | ||||
| 2013-06-30 | $1.04B 10-Q · filed 2014-07-24 | $2.04B 10-Q · filed 2014-07-24 | $3.18B derived: sum of 3 quarters · filed 2015-02-13 | $4.25B derived: sum of 4 quarters · filed 2015-02-13 | ||||
| 2013-03-31 | $994.00M 10-Q · filed 2014-04-29 | $2.14B derived: sum of 2 quarters · filed 2015-02-13 | $3.21B derived: sum of 3 quarters · filed 2015-02-13 | $4.21B derived: sum of 4 quarters · filed 2015-02-13 | ||||
| 2012-12-31 | $1.14B derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $2.21B derived: sum of 2 quarters · filed 2015-02-13 | $3.22B derived: sum of 3 quarters · filed 2015-02-13 | $4.22B 10-K · filed 2015-02-13 | ||||
| 2012-09-30 | $1.07B 10-Q · filed 2013-10-23 | $2.08B derived: sum of 2 quarters · filed 2013-10-23 | $3.08B 10-Q · filed 2013-10-23 | $4.29B derived: sum of 4 quarters · filed 2014-02-14 | ||||
| 2012-06-30 | $1.00B 10-Q · filed 2013-07-25 | $2.01B 10-Q · filed 2013-07-25 | $3.22B derived: sum of 3 quarters · filed 2014-02-14 | $4.24B derived: sum of 4 quarters · filed 2014-02-14 | ||||
| 2012-03-31 | $1.00B 10-Q · filed 2013-04-25 | $2.22B derived: sum of 2 quarters · filed 2014-02-14 | $3.24B derived: sum of 3 quarters · filed 2014-02-14 | $4.28B derived: sum of 4 quarters · filed 2014-02-14 | ||||
| 2011-12-31 | $1.22B derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-14 | $2.23B derived: sum of 2 quarters · filed 2014-02-14 | $3.27B derived: sum of 3 quarters · filed 2014-02-14 | $4.20B 10-K · filed 2014-02-14 | ||||
| 2011-09-30 | $1.02B 10-Q · filed 2012-10-24 | $2.06B derived: sum of 2 quarters · filed 2012-10-24 | $2.99B 10-Q · filed 2012-10-24 | $3.99B derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2011-06-30 | $1.04B 10-Q · filed 2012-07-25 | $1.97B 10-Q · filed 2012-07-25 | $2.97B derived: sum of 3 quarters · filed 2013-02-15 | $3.86B derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2011-03-31 | $928.00M 10-Q · filed 2012-04-26 | $1.93B derived: sum of 2 quarters · filed 2013-02-15 | $2.82B derived: sum of 3 quarters · filed 2013-02-15 | $3.71B derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2010-12-31 | $1.00B derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $1.89B derived: sum of 2 quarters · filed 2013-02-15 | $2.79B derived: sum of 3 quarters · filed 2013-02-15 | $3.69B 10-K · filed 2013-02-15 | ||||
| 2010-09-30 | $892.00M 10-Q · filed 2011-10-27 | $1.79B derived: sum of 2 quarters · filed 2011-10-27 | $2.69B 10-Q · filed 2011-10-27 | $3.86B derived: sum of 4 quarters · filed 2012-02-17 | ||||
| 2010-06-30 | $894.00M 10-Q · filed 2011-07-28 | $1.79B 10-Q · filed 2011-07-28 | $2.96B derived: sum of 3 quarters · filed 2012-02-17 | $3.92B derived: sum of 4 quarters · filed 2012-02-17 | ||||
| 2010-03-31 | $900.00M 10-Q · filed 2011-04-28 | $2.07B derived: sum of 2 quarters · filed 2012-02-17 | $3.02B derived: sum of 3 quarters · filed 2012-02-17 | $3.94B derived: sum of 4 quarters · filed 2012-02-17 | ||||
| 2009-12-31 | $1.17B derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17 | $2.12B derived: sum of 2 quarters · filed 2012-02-17 | $3.04B derived: sum of 3 quarters · filed 2012-02-17 | $3.95B 10-K · filed 2012-02-17 | ||||
| 2009-09-30 | $953.00M 10-Q · filed 2010-10-26 | $1.12B 10-Q · filed 2009-10-22 | $1.88B derived: sum of 2 quarters · filed 2010-10-26 | $2.78B 10-Q · filed 2010-10-26 | $3.26B 10-Q · filed 2009-10-22 | $3.41B derived: sum of 4 quarters · filed 2011-02-18 | ||
| 2009-06-30 | $922.00M 10-Q · filed 2010-07-22 | $1.08B 10-Q · filed 2009-07-23 | $1.82B 10-Q · filed 2010-07-22 | $2.14B 10-Q · filed 2009-07-23 | $2.46B derived: sum of 3 quarters · filed 2011-02-18 | $3.66B derived: sum of 4 quarters · filed 2011-02-18 | ||
| 2009-03-31 | $901.00M 10-Q · filed 2010-04-29 | $1.53B derived: sum of 2 quarters · filed 2011-02-18 | $2.74B derived: sum of 3 quarters · filed 2011-02-18 | $3.91B derived: sum of 4 quarters · filed 2011-02-18 | ||||
| 2008-12-31 | $633.00M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-18 | $1.84B derived: sum of 2 quarters · filed 2011-02-18 | $3.01B derived: sum of 3 quarters · filed 2011-02-18 | $4.14B 10-K · filed 2011-02-18 | ||||
| 2008-09-30 | $1.21B 10-Q · filed 2009-10-22 | $2.37B derived: sum of 2 quarters · filed 2009-10-22 | $3.51B 10-Q · filed 2009-10-22 | |||||
| 2008-06-30 | $1.17B 10-Q · filed 2009-07-23 | $2.30B 10-Q · filed 2009-07-23 | ||||||
| 2007-12-31 | $3.94B 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |